Quest for biomarkers of treatment-resistant depression: Shifting the paradigm toward risk

Frontiers in Psychiatry

Volumn 4, Issue JUN, 2013, Pages

  Smith, Donald F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarkers; Brainl imaging; Cytokines; Depressive disorders; Experimental design; Immune system; Treatment resistance

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; DEXAMETHASONE; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 6; PRASTERONE; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TUMOR NECROSIS FACTOR ALPHA;

BLOOD FLOW; CEREBROSPINAL FLUID ANALYSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ELECTROCONVULSIVE THERAPY; EPIGENETICS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC POLYMORPHISM; HEREDITY; HOPELESSNESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MAJOR DEPRESSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALIVA ANALYSIS; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TREATMENT RESISTANT DEPRESSION;

EID: 84884541281     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00057     Document Type: Review

References (55)

1. Aklillu, E., Karlsson, S., Zachrisson, O. O., Ozdemir, V., and Agren, H. (2009). Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet. Genomics 19, 267-275. doi:10.1097/FPC.0b013e328328d4d3
2. Anttila, S., Huuhka, K., Huuhka, M., Rontu, R., Hurme, M., Leinonen, E., et al. (2007). Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J. Neural Transm. 114, 1065-1068. doi:10.1007/s00702-007-0705-9
3. Autry, A. E., and Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64, 238-258. doi:10.1124/pr.111.005108
4. Bale, T. L., Baram, T. Z., Brown, A. S., Goldstein, J. M., Insel, T. R., McCarthy, M. M., et al. (2010). Early life programming and neurodevelopmental disorders. Biol. Psychiatry 68, 314-319. doi:10.1016/j.biopsych.2010.05.028
5. Bauer, M. E., Papadopoulos, A., Poon, L., Perks, P., Lightman, S. L., Checkley, S., et al. (2002). Dexamethasone-induced effects on lymphocyte distribution and expression of adhesion molecules in treatment-resistant depression. Psychiatry Res. 113, 1-15. doi:10.1016/S0165-1781(02)00243-3
6. Bauer, M. E., Papadopoulos, A., Poon, L., Perks, P., Lightman, S. L., Checkley, S., et al. (2003). Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 28, 49-65. doi:10.1016/S0306-4530(02)00009-4
7. Berlim, M. T., Fleck, M. P., and Turecki, G. (2008). Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann. Med. 40, 149-159. doi:10.1080/07853890701769728
8. Berlim, M. T., and Turecki, G. (2007). Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can. J. Psychiatry 52, 46-54.
9. Bowell, T., and Kemp, G. (2005). Critical Thinking. A Concise Guide, 2nd Edn. New York, NY: Routledge.
10. Brady, L. S., and Insel, T. R. (2012). Translating discoveries into medicine: psychiatric drug development in 2011. Neuropsychopharmacology 37, 281-283. doi:10.1038/npp.2011.106
11. Cardoso de Almeida, J. R., and Phillips, M. L. (2013). Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives. Biol. Psychiatry 73, 111-118. doi:10.1016/j.biopsych.2012.06.010
12. Chen, C. H., Ridler, K., Suckling, J., Williams, S., Fu, C. H., Merlo-Pich, E., et al. (2007). Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol. Psychiatry 62, 407-414. doi:10.1016/j.biopsych.2006.09.018
13. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., et al. (2010). A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446-457. doi:10.1016/j.biopsych.2009.09.033
14. Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 53, 649-659. doi:10.1016/S0006-3223(03)00231-2
15. Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., et al. (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*) study. Psychiatr. Clin. North Am. 26, 457-494. doi:10.1016/S0193-953X(02)00107-7
16. Fernandes, B., Gama, C. S., Massuda, R., Torres, M., Camargo, D., Kunz, M., et al. (2009). Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neurosci. Lett. 453, 195-198. doi:10.1016/j.neulet.2009.02.032
17. Frey, B. N., Andreazza, A. C., Houenou, J., Jamain, S., Goldstein, B. I., Frye, M. A., et al. (2013). Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry 47, 321-332. doi:10.1177/0004867413478217
18. Gilovich, T. (1993). How We Know What Isn't So. The Fallibility of Human Reason in Everyday Life. New York, NY: The Free Press.
19. Hoflich, A., Baldinger, P., Savli, M., Lanzenberger, R., and Kasper, S. (2012). Imaging treatment effects in depression. Rev. Neurosci. 23, 227-252.
20. Ingle, D. J. (1972). Fallacies and errors in the wonderlands of biology, medicine, and Lewis Carroll. Perspect. Biol. Med. 15, 254-281.
21. Jaenisch, R., and Bird, A. (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33, 245-254. doi:10.1038/ng1089
22. Li, B., Liu, L., Friston, K. J., Shen, H., Wang, L., Zeng, L. L., et al. (2012). A treatment-resistant default mode subnetwork in major depression. Biol. Psychiatry (in press). doi:10.1016/j.biopsych.2012.11.007
23. Liu, F., Guo, W., Yu, D., Gao, Q., Gao, K., Xue, Z., et al. (2012). Classification of different therapeutic responses of major depressive disorder with multivariate pattern analysis method based on structural MR scans. PLoS ONE 7:e40968. doi:10.1371/journal.pone.0040968
24. Macaluso, M., and Preskorn, S. H. (2012). How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction. J. Psychiatr. Pract. 18, 118-121. doi:10.1097/01.pra.0000413277.11091.25
25. Markopoulou, K., Papadopoulos, A., Juruena, M. F., Poon, L., Pariante, C. M., and Cleare, A. J. (2009). The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology 34, 19-26. doi:10.1016/j.psyneuen.2008.08.004
26. Martin, R. M. (1997). Scientific Thinking. Peterborough, ON: Broadview Press.
27. Mayberg, H. S. (2007). Defining the neural circuitry of depression: toward a new nosology with therapeutic implications. Biol. Psychiatry 61, 729-730. doi:10.1016/j.biopsych.2007.01.013
28. Mayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., et al. (2000). Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 48, 830-843. doi:10.1016/S0006-3223(00)01036-2
29. Miller, A. H., Maletic, V., and Raison, C. L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741. doi:10.1016/j.biopsych.2008.11.029
30. Naish, J. H., Baldwin, R. C., Patankar, T., Jeffries, S., Burns, A. S., Taylor, C. J., et al. (2006). Abnormalities of CSF flow patterns in the cerebral aqueduct in treatment-resistant late-life depression: a potential biomarker of microvascular angiopathy. Magn. Reson. Med. 56, 509-516. doi:10.1002/mrm.20999
31. O'Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V., and Dinan, T. G. (2007). Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41, 326-331. doi:10.1016/j.jpsychires.2006.05.013
32. Pariante, C. M., and Miller, A. H. (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49, 391-404. doi:10.1016/S0006-3223(00)01088-X
33. Perlis, R. H. (2013). A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol. Psychiatry (in press). doi:10.1016/j.biopsych.2012.12.007
34. Purcell, S. M. (2013). Antidepressant response and polygenes. Biol. Psychiatry 73, 600-601. doi:10.1016/j.biopsych.2013.01.023
35. Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., et al. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31-41. doi:10.1001/2013.jamapsychiatry.4
36. Rothschild, A. J. (2003). Challenges in the treatment of depression with psychotic features. Biol. Psychiatry 53, 680-690. doi:10.1016/S0006-3223(02)01747-X
37. Ruhe, H. G., Rooijen, R. G., Spijker, J., Peeters, F. P., and Schene, A. H. (2012). Staging methods for treatment resistant depression. A systematic review. J. Affect. Disord. 137, 35-45. doi:10.1016/j.jad.2011.02.020
38. Rush, A. J., Warden, D., Wisniewski, S. R., Fava, M., Trivedi, M. H., Gaynes, B. N., et al. (2009). STAR*D: revising conventional wisdom. CNS Drugs 23, 627-647.
39. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122, 509-522.
40. Schlaepfer, T. E., Agren, H., Monteleone, P., Gasto, C., Pitchot, W., Rouillon, F., et al. (2012). The hidden third: improving outcome in treatment-resistant depression. J. Psychopharmacol. (Oxford) 26, 587-602. doi:10.1177/0269881111431748
41. Schneider, B., and Prvulovic, D. (2013). Novel biomarkers in major depression. Curr. Opin. Psychiatry 26, 47-53. doi:10.1097/YCO.0b013e32835a5947
42. Schosser, A., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2012). European Group for the Study of Resistant Depression (GSRD) - where have we gone so far: review of clinical and genetic findings. Eur. Neuropsychopharmacol. 22, 453-468. doi:10.1016/j.euroneuro.2012.02.006
43. Sen, S., Duman, R., and Sanacora, G. (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64, 527-532. doi:10.1016/j.biopsych.2008.05.005
44. Shah, P. J., Ebmeier, K. P., Glabus, M. F., and Goodwin, G. M. (1998). Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br. J. Psychiatry 172, 527-532. doi:10.1192/bjp.172.6.527
45. Shah, P. J., Glabus, M. F., Goodwin, G. M., and Ebmeier, K. P. (2002). Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br. J. Psychiatry 180, 434-440. doi:10.1192/bjp.180.5.434
46. Simpson, S., Baldwin, R. C., Jackson, A., and Burns, A. S. (1998). Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol. Med. 28, 1015-1026. doi:10.1017/S003329179800693X
47. Smith, D. F., Stork, B. S., Wegener, G., Ashkanian, M., Jakobsen, S., Bender, D., et al. (2009). [11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging. Psychopharmacology (Berl.) 206, 133-140. doi:10.1007/s00213-009-1587-3
48. Stewart, J. A., Kampman, O., Huuhka, M., Anttila, S., Huuhka, K., Lehtimaki, T., et al. (2009). ACE polymorphism and response to electroconvulsive therapy in major depression. Neurosci. Lett. 458, 122-125. doi:10.1016/j.neulet.2009.04.057
49. Tammen, S. A., Friso, S., and Choi, S. W. (2013). Epigenetics: the link between nature and nurture. Mol. Aspects Med. 34, 753-764. doi:10.1016/j.mam.2012.07.018
50. Tansey, K. E., Guipponi, M., Hu, X., Domenici, E., Lewis, G., Malafosse, A., et al. (2013). Contribution of common genetic variants to antidepressant response. Biol. Psychiatry 73, 679-682. doi:10.1016/j.biopsych.2012.10.030
51. Thase, M. E., and Rush, A. J. (1995). "Treatment-resistant depression," in Psychopharmacology: The Fourth Generation of Progress, eds F. E. Bloom, and D. J. Kupfer (New York: Raven Press), 1081-1097.
52. Uher, R., Perlis, R. H., Henigsberg, N., Zobel, A., Rietschel, M., Mors, O., et al. (2012). Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol. Med. 42, 967-980. doi:10.1017/S0033291711001905
53. Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., et al. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655-679. doi:10.1016/j.euroneuro.2011.07.018
54. Xiang, Y. T., Wang, G., Hu, C., Guo, T., Ungvari, G. S., Kilbourne, A. M., et al. (2012). Demographic and clinical features and prescribing patterns of psychotropic medications in patients with the melancholic subtype of major depressive disorder in China. PLoS ONE 7:e39840. doi:10.1371/journal.pone.0039840
55. Zhang, T. J., Wu, Q. Z., Huang, X. Q., Sun, X. L., Zou, K., Lui, S., et al. (2009). Magnetization transfer imaging reveals the brain deficit in patients with treatment-refractory depression. J. Affect. Disord. 117, 157-161. doi:10.1016/j.jad.2009.01.003